There have been many new developments in antifungal therapy in the past few years. Some
antifungal drugs have been reformulated to reduce toxicity (eg new lipid formulations of …

Serious fungal infections, caused mostly by opportunistic species, are increasingly common
in immunocompromised and other vulnerable patients. The use of antifungal drugs, primarily …

Due to their eukaryotic heritage, the differences between a fungal pathogen's molecular
makeup and its human host are small. Therefore, the discovery and subsequent …

Invasive fungal infections are becoming an increasingly important cause of human mortality
and morbidity, particularly for immunocompromised populations. The fungal pathogens …

Promising new compounds have recently been identified in an effort to supplement the
relatively sparse portfolio of antifungal drugs. Many of these compounds have defined …

Fungi are one of the most neglected pathogens apparent from the fact that the Amphotericin
B, a polyene antibiotic, discovered way back in 1956 is still used as a'gold standard'for …

Highlights•Fungi have a serious impact on human health, causing millions of deaths
worldwide.•Scientific advances have enabled the discovery of novel antifungals.•This review …

An increasing clinical burden of fungal disease is associated with chronic (eg chronic
pulmonary aspergillosis), systemic (eg candidemia and cryptococcal meningoencephalitis) …

Introduction: Superficial infections involving the skin and mucosa are the most common
fungal disease in humans. Fungi can also produce invasive infections (IFI), which are …

Fungal infections are a universal problem and are routinely associated with high morbidity
and mortality rates in immunocompromised patients. Existing therapies comprise five …